94 related articles for article (PubMed ID: 29349795)
1. Quality of life assumptions determine which cervical cancer screening strategies are cost-effective.
de Kok IMCM; Korfage IJ; van den Hout WB; Helmerhorst TJM; Habbema JDF; Essink-Bot ML; van Ballegooijen M
Int J Cancer; 2018 Jun; 142(11):2383-2393. PubMed ID: 29349795
[TBL] [Abstract][Full Text] [Related]
2. Health utility values of breast cancer treatments and the impact of varying quality of life assumptions on cost-effectiveness.
Kregting LM; Vrancken Peeters NJMC; Clarijs ME; Koppert LB; Korfage IJ; van Ravesteyn NT
Int J Cancer; 2024 Jul; 155(1):117-127. PubMed ID: 38478916
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of different types of human papillomavirus vaccination combined with a cervical cancer screening program in mainland China.
Mo X; Gai Tobe R; Wang L; Liu X; Wu B; Luo H; Nagata C; Mori R; Nakayama T
BMC Infect Dis; 2017 Jul; 17(1):502. PubMed ID: 28720082
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
de Kok IM; van Ballegooijen M; Habbema JD
J Natl Cancer Inst; 2009 Aug; 101(15):1083-92. PubMed ID: 19571256
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of human papillomavirus screening for cervical cancer. A review of recent modelling studies.
Holmes J; Hemmett L; Garfield S
Eur J Health Econ; 2005 Mar; 6(1):30-7. PubMed ID: 15682286
[TBL] [Abstract][Full Text] [Related]
6. VIA/VILI is more suitable for cervical cancer prevention in Chinese poverty-stricken region: a health economic evaluation.
Xie Y; Tan X; Shao H; Liu Q; Tou J; Zhang Y; Luo Q; Xiang Q
BMC Public Health; 2017 Jan; 17(1):118. PubMed ID: 28122530
[TBL] [Abstract][Full Text] [Related]
7. Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.
Kim JJ; Burger EA; Sy S; Campos NG
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27754955
[TBL] [Abstract][Full Text] [Related]
8. Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis.
Kim JJ; Campos NG; Sy S; Burger EA; Cuzick J; Castle PE; Hunt WC; Waxman A; Wheeler CM;
Ann Intern Med; 2015 Oct; 163(8):589-97. PubMed ID: 26414147
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of primary HPV screening for cervical cancer in Germany--a decision analysis.
Sroczynski G; Schnell-Inderst P; Mühlberger N; Lang K; Aidelsburger P; Wasem J; Mittendorf T; Engel J; Hillemanns P; Petry KU; Krämer A; Siebert U
Eur J Cancer; 2011 Jul; 47(11):1633-46. PubMed ID: 21482103
[TBL] [Abstract][Full Text] [Related]
10. The potential harms of primary human papillomavirus screening in over-screened women: a microsimulation study.
Naber SK; de Kok IM; Matthijsse SM; van Ballegooijen M
Cancer Causes Control; 2016 Apr; 27(4):569-81. PubMed ID: 26970740
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of cervical-cancer screening in five developing countries.
Goldie SJ; Gaffikin L; Goldhaber-Fiebert JD; Gordillo-Tobar A; Levin C; Mahé C; Wright TC;
N Engl J Med; 2005 Nov; 353(20):2158-68. PubMed ID: 16291985
[TBL] [Abstract][Full Text] [Related]
12. How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands.
Coupé VM; de Melker HE; Snijders PJ; Meijer CJ; Berkhof J
Vaccine; 2009 Aug; 27(37):5111-9. PubMed ID: 19567242
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis.
Simms KT; Laprise JF; Smith MA; Lew JB; Caruana M; Brisson M; Canfell K
Lancet Public Health; 2016 Dec; 1(2):e66-e75. PubMed ID: 29253419
[TBL] [Abstract][Full Text] [Related]
14. The cost-utility of integrated cervical cancer prevention strategies in the Ontario setting - Can we do better?
Sander B; Wong WW; Yeung MW; Ormanidhi O; Atkin K; Murphy J; Krahn M; Deeks SL
Vaccine; 2016 Apr; 34(16):1936-44. PubMed ID: 26892739
[TBL] [Abstract][Full Text] [Related]
15. Health-related quality of life as measured by the EQ-5D in the prevention, screening and management of cervical disease: A systematic review.
Ó Céilleachair A; O'Mahony JF; O'Connor M; O'Leary J; Normand C; Martin C; Sharp L
Qual Life Res; 2017 Nov; 26(11):2885-2897. PubMed ID: 28653217
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of human papillomavirus-16/18 genotyping in cervical cancer screening.
Huh WK; Williams E; Huang J; Bramley T; Poulios N
Appl Health Econ Health Policy; 2015 Feb; 13(1):95-107. PubMed ID: 25385310
[TBL] [Abstract][Full Text] [Related]
17. Cost-Utility Analysis of Human Papillomavirus Vaccination and Cervical Screening on Cervical Cancer Patient in Indonesia.
Setiawan D; Dolk FC; Suwantika AA; Westra TA; WIlschut JC; Postma MJ
Value Health Reg Issues; 2016 May; 9():84-92. PubMed ID: 27881267
[TBL] [Abstract][Full Text] [Related]
18. Modeled cost-effectiveness of transforaminal lumbar interbody fusion compared with posterolateral fusion for spondylolisthesis using N(2)QOD data.
Carreon LY; Glassman SD; Ghogawala Z; Mummaneni PV; McGirt MJ; Asher AL
J Neurosurg Spine; 2016 Jun; 24(6):916-21. PubMed ID: 26895529
[TBL] [Abstract][Full Text] [Related]
19. The budget impact of cervical cancer screening using HPV primary screening.
Wright T; Huang J; Baker E; Garfield S; Hertz D; Cox JT
Am J Manag Care; 2016 Mar; 22(3):e95-105. PubMed ID: 26978241
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
